Answers are grounded in this paper and cite their sources.
Aim: To determine the impact of galectin-3 levels on the progression of metabolic disorders and structural-functional changes in the myocardium and blood vessels in patients with concomitant systemic arterial hypertension (AH) and type 2 diabetes mellitus (type 2 DM). Methods: Ninety-five patients with hypertension stage II grade 2 (53 males and 42 females) were examined. The patients were separated: group 1 (n = 32) patients with AH, without carbohydrate metabolism disorders; group 2 (n = 30) patients with AH and pre-diabetes; group 3 (n = 33) concomitant AH and type 2 DM. Carbohydrate metabolism, insulin resistance parameters and galectin-3 levels were measured. Echocardiography was performed to determine the structural-functional condition of the heart. Estimation of the intima-media complex thickness of the common carotid artery was performed by duplex ultrasound scanning. Results: Hypertrophy of the left ventricular myocardium is most evident in patients with AH and type 2 DM compared with groups 1 and 2, and the control group (P < 0.05). The levels of galectin-3 in the group with concomitant hypertension and type 2 DM were higher than in groups 1 and 2, and the control group (P < 0.05). A positive correlation was revealed between the level of galectin-3, indices of insulin resistance, and structural-functional cardiac and vessel remodeling. Conclusion: Galectin-3 levels in serum are significantly linked with indices of insulin resistance and cardiovascular remodeling.
No takes yet. Share an insight, caveat, or question.
Lesya Bobronnikova (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: